Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUCOVAC 2
2025-521217-46-00Phase 4Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Fluzone Trivalent, Vaxigrip and Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen in influenza, sponsored by CHU Saint-Etienne. Primary endpoint: Change in frequency of nasal resident memory lymphocytes and migration marker expression on peripheral memory lymphocytes. Started Dec 2025; status: completed.
02
Drugs
Fluzone TrivalentVaxigripInfluenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen
03
Conditions
influenza
Beyond the preview
Go deeper on 2025-521217-46-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521217-46-00.